6533b874fe1ef96bd12d6362

RESEARCH PRODUCT

Survival in young patients with intermediate-/high-risk myelofibrosis: Estimates derived from databases for non transplant patients

Francesco PassamontiAyalew TefferiSergio SiragusaFrancisco Cervantes

subject

AdultMalemedicine.medical_specialtyTransplantation ConditioningAdolescentmedicine.medical_treatmentbone marrow transplantationContext (language use)myelofibrosisHematopoietic stem cell transplantationKaplan-Meier EstimateSettore MED/15 - Malattie Del Sanguemyelofibrosis survivalYoung AdultPharmacotherapyInternal medicinemedicineHumansTransplantation HomologousYoung adultMyelofibrosisRetrospective Studiesbusiness.industryAge FactorsHematopoietic Stem Cell TransplantationRetrospective cohort studyHematologyMiddle Agedmedicine.diseaseSurgeryTransplantationmyelofibrosis; bone marrow transplantationPrimary MyelofibrosisFemaleTransplantation ConditioningbusinessFollow-Up Studies

description

Recent studies have suggested that allogenic stem cell transplantation (allo-SCT) might be a better treatment option, compared to drug therapy, for young patients with high-/intermediate-risk primary myelofibrosis (PMF). However, there are no controlled studies that validate this contention and allo-SCT is associated with a substantial risk of procedure-related mortality and morbidity. In a retrospective analysis of nontransplant PMF patients, who were both young (age <60 years) and with high-/intermediate-risk disease, 1- and 3-year survival estimates were 87% and 55%, 95% and 77%, 71% and 58%, respectively, involving patients seen at three different centers with expertise in PMF; these data did not appear to be inferior to those published in the context of either myeloablative or reduced-intensity conditioning allo-SCT. These observations underscore the need for controlled studies to accurately assess the value of allo-SCT in PMF.

yearjournalcountryeditionlanguage
2009-01-01
10.1002/ajh.21342http://hdl.handle.net/11383/2023323